Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 186

The DOI matches its Crossref record.

Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy 18Fluorodeoxyglucose-PET-CT scan

Open access
Aerts, Hugo J.W.L., van Baardwijk, Angela A.W., Petit, Steven F., Offermann, Claudia, Loon, Judith van, Houben, Ruud, Dingemans, Anne-Marie C., Wanders, Rinus, Boersma, Liesbeth, Borger, Jacques, Bootsma, Gerben, Geraedts, Wiel, Pitz, Cordula, Simons, Jean, Wouters, Bradly G., Oellers, Michel, Lambin, Philippe, Bosmans, Geert, Dekker, Andre L.A.J., Ruysscher, Dirk De · 2009 · Radiotherapy and Oncology

Abstract

Background and Purpose Non-small cell lung cancer (NSCLC) tumours are mostly heterogeneous. We hypothesized that areas within the tumour with a high pre-radiation 18F-deoxyglucose (FDG) uptake, could identify residual metabolic-active areas, ultimately enabling selective-boosting of tumour sub-volumes. Material and Methods Fifty-five patients with inoperable stage I-III NSCLC treated with chemo-radiation or with radiotherapy alone were included. For each patient one pre-radiotherapy and one post-radiotherapy FDG-PET-CT scans was available. Twenty-two patients showing persistent FDG-uptake in the primary tumour after radiotherapy were analyzed. Overlap-fractions (OF) were calculated between standardized uptake value (SUV) threshold-based auto-delineations on the pre- and post-radiotherapy scan. Results Patients with residual metabolic-active areas within the tumour had a significantly worse survival compared to individuals with a complete metabolic response (p=0.002). The residual metabolic-active areas within the tumour largely corresponded (OF>70%) with the 50%SUV high FDG-uptake area of the pre-radiotherapy scan. The hotspot within the residual area (90%SUV) was completely within the GTV (OF=100%), and had a high overlap with the pre-radiotherapy 50%SUV threshold (OF>84%). Conclusions The location of residual metabolic-active areas within the primary tumour after therapy corresponded with the original high FDG-uptake areas pre-radiotherapy. Therefore, a single pre-treatment FDG-PET-CT scan allows for the identification of residual metabolic-active areas.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.radonc.2009.03.006

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 186

Metadata

Authors
Aerts, H. J. W. L., van Baardwijk, A. A. W., Petit, S. F., Offermann, C., Loon, J. V., Houben, R., Dingemans, A.-M. C., Wanders, R., Boersma, L., Borger, J., Bootsma, G., Geraedts, W., Pitz, C., Simons, J., Wouters, B. G., Oellers, M., Lambin, P., Bosmans, G., Dekker, A. L. A. J., & Ruysscher, D. D.
Venue
Radiotherapy and Oncology
Publisher
Elsevier BV
Published
2009-06
Volume
91
Issue
3
Pages
386-392
ISSN
0167-8140 (ISSN-L)
OpenAlex
W2028760979
Cited by
186
References
0
FWCI
12.96
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy 18Fluorodeoxyglucose-PET-CT scan. https://app.cochat.ai/papers/10.1016/j.radonc.2009.03.006
The paper
Aerts, H. J. W. L., van Baardwijk, A. A. W., Petit, S. F., Offermann, C., Loon, J. V., Houben, R., Dingemans, A.-M. C., Wanders, R., Boersma, L., Borger, J., Bootsma, G., Geraedts, W., Pitz, C., Simons, J., Wouters, B. G., Oellers, M., Lambin, P., Bosmans, G., Dekker, A. L. A. J., & Ruysscher, D. D. (2009). Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy 18Fluorodeoxyglucose-PET-CT scan. Radiotherapy and Oncology. https://doi.org/10.1016/j.radonc.2009.03.006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.